Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

Synovial Sarcoma, X Breakpoint 2 (SSX2) (Middle Region) Peptid

SSX2 Reaktivität: Human Wirt: Synthetic BP, WB
Produktnummer ABIN8113273
168,15 €
Zzgl. Versandkosten 20,00 € und MwSt
100 μg
Lieferung nach: Deutschland
Lieferung in 6 bis 9 Werktagen

Kurzübersicht für Synovial Sarcoma, X Breakpoint 2 (SSX2) (Middle Region) Peptid (ABIN8113273)

Target

SSX2 (Synovial Sarcoma, X Breakpoint 2 (SSX2))

Spezies

Human

Quelle

  • 4
Synthetic

Applikation

Blocking Peptide (BP), Western Blotting (WB)
  • Protein Region

    Middle Region

    Verwendungszweck

    SSX2 Peptide - middle region

    Sequenz

    TFGRLQGISP KIMPKKPAEE G NDSEEVPEAS GPQNDGKELC PPGKPTTS
  • Applikationshinweise

    Optimal working dilution should be determined by the investigator.

    Kommentare

    This is a synthetic peptide designed for use in combination with anti-SSX2 Antibody (ARP51721_P050),. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications. Please inquire for more details.

    Beschränkungen

    Nur für Forschungszwecke einsetzbar
  • Format

    Lyophilized

    Rekonstitution

    Add 100 µL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

    Buffer

    Lyophilized powder

    Lagerung

    -20 °C

    Informationen zur Lagerung

    For longer periods of storage, store at -20 °C. Avoid repeat freeze-thaw cycles.
  • Target

    SSX2 (Synovial Sarcoma, X Breakpoint 2 (SSX2))

    Hintergrund

    Background Information: SSX2 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X,18) translocation characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are probably responsible for transforming activity. Two transcript variants encoding distinct isoforms have been identified for this gene.

    Alternative Symbols: CT5.2a, HD21, HOM-MEL-40, SSX

    Molekulargewicht

    24kDa

    Gen-ID

    6757

    NCBI Accession

    NP_783629

    UniProt

    Q16385
Sie sind hier:
Chat with us!